TipRanks
Go Ultimate55% OFF

Patricia Allen Insider Profile

11 Followers

Patricia Allen, Director at Zenas BioPharma, Inc., holds 19.86K shares in Zenas BioPharma, Inc. (Ticker: ZBIO), holds 0.00 shares in Larimar Therapeutics (Ticker: LRMR), holds ― shares in Kineta (Ticker: KANT). Most recently, Patricia Allen Bought ― shares of Zenas BioPharma, Inc. on Feb 13, 2026 for an estimated value of $499.75K.

Patricia Allen's Trading History

ZBIO
Zenas BioPharma, Inc.
Feb 13, 2026DirectorInformative Buy499.75K$563.83K
DCPH
Deciphera Pharmaceuticals
Jan 28, 2020―Uninformative Sell1.65M$0.00
ALNY
Alnylam Pharma
Apr 24, 2009VP of Finance and TreasurerUninformative Sell440.50K$192.22K
KANT
Kineta
――――
LRMR
Larimar Therapeutics
―CFO―$0.00

You May Also Like

Patricia Allen insider profile FAQ

What is the percentage of profitable transactions made by Patricia Allen?
The percentage of profitable transactions made by Patricia Allen is 50%.
What is the average return per transaction made by Patricia Allen?
The average return per transaction made by Patricia Allen is -12.10%.
What stocks does Patricia Allen hold?
Patricia Allen holds: ZBIO, LRMR, KANT, DCPH, ALNY stocks.
What was Patricia Allen’s latest transaction?
Patricia Allen’s latest transaction was an Informative Buy of $499.75K.
What was Patricia Allen's most profitable transaction?
Patricia Allen’s most profitable transaction was an Informative Buy of ZBIO stock on February 13, 2026. The return on the trade was 7.50%.
What is Patricia Allen's role in Zenas BioPharma, Inc.?
Patricia Allen's role in Zenas BioPharma, Inc. is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.